{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:10:00Z","timestamp":1717287000630},"reference-count":45,"publisher":"Pan African Medical Journal","content-domain":{"domain":["panafrican-med-journal.com"],"crossmark-restriction":true},"short-container-title":["Pan Afr Med J"],"DOI":"10.11604\/pamj.2024.47.114.37278","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:53:37Z","timestamp":1710140017000},"update-policy":"http:\/\/dx.doi.org\/10.11604\/pamj.2016.07.30.0001","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis"],"prefix":"10.11604","volume":"47","author":[{"given":"Hammad","family":"Ali Fadlalmola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled Mohammed","family":"Al-Sayaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulqader Abdlah","family":"Al-Hebshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhanad","family":"Alhujaily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa Omar","family":"Alyamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa Abdulrhman","family":"Alem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona Hamza","family":"Syrafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afrah Hassan","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathi Abdelrazig","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hager Hassan","family":"Abdalrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Abdelkrim","family":"Abdelmalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neimat Mahmoud","family":"Abdalrhman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alamin Mustafa","family":"Eltayeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4870","published-online":{"date-parts":[[2024]]},"reference":[{"issue":"10225","key":"ref1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov B Purcell CA Levey AS Smith M Abdoli A Abebe M et al","year":"2020","unstructured":"1. Bikbov B Purcell CA Levey AS Smith M Abdoli A Abebe M et al Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet (London, England) 2020 Feb 2939510225 70933","journal-title":"Lancet (London, England)"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.ajkd.2018.08.013","article-title":"Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium","volume":"73","author":"Inker LA Grams ME Levey AS Coresh J Cirillo M Collins JF et al","year":"2019","unstructured":"2. Inker LA Grams ME Levey AS Coresh J Cirillo M Collins JF et al Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium Am J Kidney Dis 2019 Feb732 206217","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ndt\/gft443","article-title":"The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients","volume":"29","author":"Zumbrennen-Bullough K Babitt JL","year":"2014","unstructured":"3. Zumbrennen-Bullough K Babitt JL The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients Nephrol Dial Transplant 2014 Feb292 26373","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"ref4","first-page":"280","article-title":"Kidney International Supplements","volume":"2","year":"2012","unstructured":"4. Kidney International Supplements Foreword 201224 280 Accessed 9th September 2022","journal-title":"Foreword"},{"key":"ref5","first-page":"642296","article-title":"Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents","volume":"8","author":"Portol\u00e9s J Mart\u00edn L Broseta JJ Cases A","year":"2021","unstructured":"5. Portol\u00e9s J Mart\u00edn L Broseta JJ Cases A Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents Front Med (Lausanne) 2021 Mar 26 8 642296","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt JL Lin HY","year":"2012","unstructured":"6. Babitt JL Lin HY Mechanisms of anemia in CKD J Am Soc Nephrol 2012 Oct2310 16314","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1182\/blood-2007-10-115857","article-title":"Repression via the GATA box is essential for tissue-specific erythropoietin gene expression","volume":"111","author":"Obara N Suzuki N Kim K Nagasawa T Imagawa S Yamamoto MJB","year":"2008","unstructured":"7. Obara N Suzuki N Kim K Nagasawa T Imagawa S Yamamoto MJB Repression via the GATA box is essential for tissue-specific erythropoietin gene expression Blood 2008 May 1511110 522332","journal-title":"Blood"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"e25839","DOI":"10.1371\/journal.pone.0025839","article-title":"Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice","volume":"6","author":"Pan X Suzuki N Hirano I Yamazaki S Minegishi N Yamamoto M","year":"2011","unstructured":"8. Pan X Suzuki N Hirano I Yamazaki S Minegishi N Yamamoto M Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice PLoS One 2011610 e25839","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/ncomms2950","article-title":"A mouse model of adult-onset anaemia due to erythropoietin deficiency","volume":"4","author":"Yamazaki S Souma T Hirano I Pan X Minegishi N Suzuki N et al","year":"2013","unstructured":"9. Yamazaki S Souma T Hirano I Pan X Minegishi N Suzuki N et al A mouse model of adult-onset anaemia due to erythropoietin deficiency Nat Commun 20134 1950","journal-title":"Nat Commun"},{"key":"ref10","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2012","author":"McMurray J Parfrey P Adamson JW Aljama P Berns JS Bohlius J et al Kidney disease: Improving global outcomes (KDIGO) anemia work group","year":"","unstructured":"10. McMurray J Parfrey P Adamson JW Aljama P Berns JS Bohlius J et al Kidney disease: Improving global outcomes (KDIGO) anemia work group KDIGO clinical practice guideline for anemia in chronic kidney disease Kidney International Supplements 2012 279335","journal-title":"Kidney International Supplements"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis","volume":"68","author":"Shepshelovich D Rozen-Zvi B Avni T Gafter U Gafter-Gvili A","year":"2016","unstructured":"11. Shepshelovich D Rozen-Zvi B Avni T Gafter U Gafter-Gvili A Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis Am J Kidney Dis 2016 Nov685 677690","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab A Bolton WK Browne JK Egrie JC Nissenson AR Okamoto DM et al","year":"1998","unstructured":"12. Besarab A Bolton WK Browne JK Egrie JC Nissenson AR Okamoto DM et al The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 1998 Aug 273399 58490","journal-title":"N Engl J Med"},{"issue":"20","key":"ref13","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke TB Locatelli F Clyne N Eckardt KU Macdougall IC Tsakiris D et al","year":"2006","unstructured":"13. Dr\u00fceke TB Locatelli F Clyne N Eckardt KU Macdougall IC Tsakiris D et al Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 2006 Nov 1635520 207184","journal-title":"N Engl J Med"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer MA Burdmann EA Chen CY Cooper ME de Zeeuw D Eckardt KU et al","year":"2009","unstructured":"14. Pfeffer MA Burdmann EA Chen CY Cooper ME de Zeeuw D Eckardt KU et al A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 2009 Nov 1936121 201932","journal-title":"N Engl J Med"},{"issue":"20","key":"ref15","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh AK Szczech L Tang KL Barnhart H Sapp S Wolfson M et al","year":"2006","unstructured":"15. Singh AK Szczech L Tang KL Barnhart H Sapp S Wolfson M et al Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 2006 Nov 1635520 208598","journal-title":"N Engl J Med"},{"issue":"6","key":"ref16","first-page":"294","article-title":"Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study","volume":"36","author":"Granolleras C Leskopf W Shaldon S Fourcade J","year":"1991","unstructured":"16. Granolleras C Leskopf W Shaldon S Fourcade J Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study Clin Nephrol 1991 Dec366 2948","journal-title":"Clin Nephrol"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/ijms19020389","article-title":"Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease","volume":"19","author":"Kaplan JM Sharma N Dikdan S","year":"2018","unstructured":"17. Kaplan JM Sharma N Dikdan S Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease Int J Mol Sci 2018 Jan 29192 389","journal-title":"Int J Mol Sci"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.kint.2017.02.035","article-title":"Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease","volume":"92","author":"Sugahara M Tanaka T Nangaku M","year":"2017","unstructured":"18. Sugahara M Tanaka T Nangaku M Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease Kidney Int 2017 Aug922 30612","journal-title":"Kidney Int"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki M Matak P Keith B Simon MC Vaulont S Peyssonnaux C","year":"2009","unstructured":"19. Mastrogiannaki M Matak P Keith B Simon MC Vaulont S Peyssonnaux C HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice J Clin Invest 2009 May1195 115966","journal-title":"J Clin Invest"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"e25324","DOI":"10.1371\/journal.pone.0025324","article-title":"Hepcidin is involved in iron regulation in the ischemic brain","volume":"6","author":"Ding H Yan CZ Shi H Zhao YS Chang SY Yu P et al","year":"2011","unstructured":"20. Ding H Yan CZ Shi H Zhao YS Chang SY Yu P et al Hepcidin is involved in iron regulation in the ischemic brain PloS One 201169 e25324","journal-title":"PloS One"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/DDDT.S175887","article-title":"The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease","volume":"12","author":"Zhong H Zhou T Li H Zhong Z","year":"2018","unstructured":"21. Zhong H Zhou T Li H Zhong Z The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease Drug Des Devel Ther 201812 300311","journal-title":"Drug Des Devel Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"573645","DOI":"10.3389\/fphar.2020.573645","article-title":"Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis","volume":"11","author":"Zheng Q Wang Y Yang H Sun L Fu X Wei R et al","year":"2021","unstructured":"22. Zheng Q Wang Y Yang H Sun L Fu X Wei R et al Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis Front Pharmacol 2021 Jan 12 11 573645","journal-title":"Front Pharmacol"},{"key":"ref23","first-page":"2","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT TJ Chandler J Cumpston M Li T Page MJ Welch VA","year":"2019","unstructured":"23. Higgins JPT TJ Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions 2019 Chichester (UK) John Wiley & Sons2"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B Salanti G Caldwell DM Chaimani A Schmid CH Cameron C et al","year":"2015","unstructured":"24. Hutton B Salanti G Caldwell DM Chaimani A Schmid CH Cameron C et al The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med 2015 Jun 216211 77784","journal-title":"Ann Intern Med"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A Altman DG Tetzlaff J Mulrow C G\u00f8tzsche PC Ioannidis JP et al","year":"2009","unstructured":"25. Liberati A Altman DG Tetzlaff J Mulrow C G\u00f8tzsche PC Ioannidis JP et al The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 2009 Jul 2167 e1000100","journal-title":"PLoS Med"},{"key":"ref26","article-title":"Chapter 7: Considering bias and conflicts of interest among the included studies","author":"Boutron I PM Higgins JPT Altman DG Lundh A Hr\u00f3bjartsson A Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Welch VA","year":"2021","unstructured":"26. Boutron I PM Higgins JPT Altman DG Lundh A Hr\u00f3bjartsson AHiggins JPT Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Chapter 7: Considering bias and conflicts of interest among the included studies Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) 2021 Cochrane","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)"},{"issue":"25","key":"ref27","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis","volume":"385","author":"Singh AK Carroll K Perkovic V Solomon S Jha V Johansen KL et al","year":"2021","unstructured":"27. Singh AK Carroll K Perkovic V Solomon S Jha V Johansen KL et al Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis N Engl J Med 2021 Dec 1638525 23252335","journal-title":"N Engl J Med"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects","volume":"45","author":"Akizawa T Tsubakihara Y Nangaku M Endo Y Nakajima H Kohno T et al","year":"2017","unstructured":"28. Akizawa T Tsubakihara Y Nangaku M Endo Y Nakajima H Kohno T et al Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects Am J Nephrol 2017452 12735","journal-title":"Am J Nephrol"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial","volume":"67","author":"Brigandi RA Johnson B Oei C Westerman M Olbina G de Zoysa J et al","year":"2016","unstructured":"29. Brigandi RA Johnson B Oei C Westerman M Olbina G de Zoysa J et al A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial Am J Kidney Dis 2016 Jun676 86171","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia","volume":"27","author":"Holdstock L Meadowcroft AM Maier R Johnson BM Jones D Rastogi A et al","year":"2016","unstructured":"30. Holdstock L Meadowcroft AM Maier R Johnson BM Jones D Rastogi A et al Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia J Am Soc Nephrol 2016 Apr274 123444","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft AM Cizman B Holdstock L Biswas N Johnson BM Jones D et al","year":"2019","unstructured":"31. Meadowcroft AM Cizman B Holdstock L Biswas N Johnson BM Jones D et al Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis Clin Kidney J 2019 Feb121 139148","journal-title":"Clin Kidney J"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","article-title":"A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis","volume":"20","author":"Bailey CK Caltabiano S Cobitz AR Huang C Mahar KM Patel VV","year":"2019","unstructured":"32. Bailey CK Caltabiano S Cobitz AR Huang C Mahar KM Patel VV A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis BMC Nephrol 2019 Oct 16201 372","journal-title":"BMC Nephrol"},{"issue":"8","key":"ref33","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial","volume":"15","author":"Akizawa T Nangaku M Yonekawa T Okuda N Kawamatsu S Onoue T et al","year":"2020","unstructured":"33. Akizawa T Nangaku M Yonekawa T Okuda N Kawamatsu S Onoue T et al Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial Clin J Am Soc Nephrol 2020 Aug 7158 11551165","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap DYH McMahon LP Hao CM Hu N Okada H Suzuki Y et al","year":"2021","unstructured":"34. Yap DYH McMahon LP Hao CM Hu N Okada H Suzuki Y et al Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors Nephrology (Carlton) 2021 Feb262 105118","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/biomedicines9050468","article-title":"HIF-alpha Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review","volume":"9","author":"Hirota K","year":"2021","unstructured":"35. Hirota K HIF-alpha Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review Biomedicines 2021 Apr 2495 468","journal-title":"Biomedicines"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cpdd.83","article-title":"Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863","volume":"3","author":"Johnson BM Stier BA Caltabiano S","year":"2014","unstructured":"36. Johnson BM Stier BA Caltabiano S Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863 Clin Pharmacol Drug Dev 2014 Mar32 10917","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.117.242503","article-title":"Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia","volume":"363","author":"Ariazi JL Duffy KJ Adams DF Fitch DM Luo L Pappalardi M et al","year":"2017","unstructured":"37. Ariazi JL Duffy KJ Adams DF Fitch DM Luo L Pappalardi M et al Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia J Pharmacol Exp Ther 2017 Dec3633 336347","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1172\/JCI31750","article-title":"HIF-1 and HIF-2: working alone or together in hypoxia?","volume":"117","author":"Ratcliffe PJ","year":"2007","unstructured":"38. Ratcliffe PJ HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 2007 Apr1174 8625","journal-title":"J Clin Invest"},{"issue":"16","key":"ref39","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou PP Liu Q Unger TL Rha J Davidoff O Keith B et al","year":"2010","unstructured":"39. Kapitsinou PP Liu Q Unger TL Rha J Davidoff O Keith B et al Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia Blood 2010 Oct 2111616 303948","journal-title":"Blood"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel HL Mercurio AM","year":"2013","unstructured":"40. Goel HL Mercurio AM VEGF targets the tumour cell Nat Rev Cancer 2013 Dec1312 87182","journal-title":"Nat Rev Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.phrs.2015.11.003","article-title":"Pathophysiology and pharmacological targets of VEGF in diabetic macular edema","volume":"103","author":"Fogli S Mogavero S Egan CG Del Re M Danesi R","year":"2016","unstructured":"41. Fogli S Mogavero S Egan CG Del Re M Danesi R Pathophysiology and pharmacological targets of VEGF in diabetic macular edema Pharmacol Res 2016 Jan 103 14957","journal-title":"Pharmacol Res"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1744-9987.12962","article-title":"A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients","volume":"24","author":"Tsubakihara Y Akizawa T Nangaku M Onoue T Yonekawa T Matsushita H et al","year":"2020","unstructured":"42. Tsubakihara Y Akizawa T Nangaku M Onoue T Yonekawa T Matsushita H et al A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients Ther Apher Dial 2020 Apr242 108114","journal-title":"Ther Apher Dial"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","article-title":"Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease","volume":"24","author":"Vaziri ND Zhou XJ","year":"2009","unstructured":"43. Vaziri ND Zhou XJ Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol Dial Transplant 2009 Apr244 10828","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough PA Barnhart HX Inrig JK Reddan D Sapp S Patel UD et al","year":"2013","unstructured":"44. McCullough PA Barnhart HX Inrig JK Reddan D Sapp S Patel UD et al Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease Am J Nephrol 2013376 54958","journal-title":"Am J Nephrol"},{"key":"ref45","first-page":"396","article-title":"Comparative Gene Expression Analysis of Two Mouse Models of Autism: Transcriptome Profiling of the BTBR and En2 (-\/-) Hippocampus","volume":"10","author":"Provenzano G Corradi Z Monsorno K Fedrizzi T Ricceri L Scattoni ML et al","year":"2016","unstructured":"45. Provenzano G Corradi Z Monsorno K Fedrizzi T Ricceri L Scattoni ML et al Comparative Gene Expression Analysis of Two Mouse Models of Autism: Transcriptome Profiling of the BTBR and En2 (-\/-) Hippocampus Front Neurosci 2016 Aug 2510 396","journal-title":"Front Neurosci"}],"container-title":["The Pan African Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.panafrican-med-journal.com\/\/content\/article\/47\/114\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:09:49Z","timestamp":1717211389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/\/content\/article\/47\/114\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":45,"URL":"https:\/\/doi.org\/10.11604\/pamj.2024.47.114.37278","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}